Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer

(2013) Heidi D. Nelson   ANNALS OF INTERNAL MEDICINE

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

(2011) K Metcalfe et al.   BRITISH JOURNAL OF CANCER

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

(2011) Antonis C Antoniou et al.   HUMAN MOLECULAR GENETICS

Medication to prevent breast cancer - too much to swallow?

(2011) Sandra L Harvey et al.   MEDICAL JOURNAL OF AUSTRALIA

Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families

(2011) David L. Duffy et al.   Twin Research and Human Genetics

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

(2010) Kerryn W. Reding et al.   BREAST CANCER RESEARCH AND TREATMENT

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation inBRCA1orBRCA2

(2010) Kathleen E. Malone et al.   JOURNAL OF CLINICAL ONCOLOGY

Control of mammary stem cell function by steroid hormone signalling

(2010) Marie-Liesse Asselin-Labat et al.   NATURE

Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

(2009) Belinda E. Kiely et al.   BREAST CANCER RESEARCH AND TREATMENT

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

(2009) Kala Visvanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

(2009) Monika K. Graeser et al.   JOURNAL OF CLINICAL ONCOLOGY

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status

(2009) A. W. Kurian et al.   JNCI-Journal of the National Cancer Institute

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

(2009) T. R. Rebbeck et al.   JNCI-Journal of the National Cancer Institute

Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers

(2008) Maria M Litwiniuk et al.   BMC CANCER

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

(2008) Kelly A. Metcalfe et al.   INTERNATIONAL JOURNAL OF CANCER

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

(2008) Nienke M. van der Velde et al.   INTERNATIONAL JOURNAL OF CANCER

Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group

(2008) Kelly A. Metcalfe et al.   JOURNAL OF CLINICAL ONCOLOGY